¼¼°èÀÇ ÇâÁø±ÕÁ¦ ½ÃÀå º¸°í¼­ : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, Áö¿ªº°(2024-2032³â)
Antifungal Drugs Market Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), and Region 2024-2032
»óǰÄÚµå : 1541719
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 147 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,255,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,674,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,094,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â 151¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ¿¹Ãø ±â°£ µ¿¾È 3.1%ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀ̸ç 2032³â¿¡´Â 201¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

ÇâÁø±ÕÁ¦´Â ÇǺÎ, ¸ð¹ß ¹× ¼ÕÅéÀÇ °õÆÎÀÌ °¨¿°À» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀǾàǰÀ» ÀǹÌÇÕ´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â Ç×Áø±ÕÁ¦·Î´Â Æú¸®¿£°è, ¾ÆÁ¹°è, ¾Ë¸±¾Æ¹Î°è µîÀÌ ÀÖ½À´Ï´Ù. À̵éÀº Ä­µð´Ù³ª ¹ú·¹ µîÀÇ Áø±ÕÀ̳ª ÇǺλç»ó±ÕÀ» ÁßÈ­ÇØ, ¹«Á», ¹é¼±, ¾Æ½ºÆä¸£±æ·ç½ºÁõ, Ä­µð´ÙÁõ, Áø±Õ¼º ¼ö¸·¿°ÀÇ Ä¡·á¸¦ µ½½À´Ï´Ù. ÀÌµé ¾àÁ¦´Â ½ÃÆÇ¾à(OTC)À¸·Î¼­ ĸ½¶Á¦, °ÖÁ¦, ¾×Á¦, Á¤Á¦ ¶Ç´Â Áø±Õ °¨¿°À» ÃÖ¼ÒÈ­ÇÏ°í ¿¹¹æÇϱâ À§ÇØ Ç÷·ù¿¡ Á÷Á¢ ÁÖÀÔÇÏ´Â Á¤¸Æ ÁÖ»ç¾×ÀÌ ÀϹÝÀûÀ¸·Î ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

Ç×Áø±ÕÁ¦ ½ÃÀå °æÇâ

°õÆÎÀÌ °¨¿°À̳ª ¿ø³» °¨¿°ÀÇ À¯ÇàÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀå¿¡ ¹àÀº Àü¸ÁÀ» °¡Á®¿À´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Ç×Áø±ÕÁ¦´Â º´¿ø ³»ÀÇ ¿À¿°µÈ Ç¥¸é°ú ½Àµµ°¡ ³ôÀº ȯ°æ¿¡ ³ëÃâµÇ¾î ¹ß»ýÇÏ´Â Àü½Å¼º ¹× Ç¥À缺 °¨¿° ¸ðµÎ¿¡ È¿°úÀûÀÔ´Ï´Ù. °Ô´Ù°¡ µµ½Ã¿¡¼­µµ ³óÃÌ¿¡¼­µµ ½ÃÆÇ¾àÀ» ¼Õ½±°Ô ÀÔ¼öÇÒ ¼ö ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ´ëÁßÀÇ °Ç°­ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °æ½Ã °¨¿°À» Àû½Ã¿¡ Ä¡·áÇϱâ À§ÇØ OTC Ä¡·á¸¦ ¼±ÅÃÇÏ´Â ¼ÒºñÀÚ°¡ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä§½À¼º Áø±Õ °¨¿°ÀÇ Ä¡·á¿ë ÇÕ¼º°ú ¹ÝÇÕ¼º ¾ÆÁ¹°è È­ÇÕ¹°ÀÇ °³¹ß µî ´Ù¾çÇÑ Á¦Ç° Çõ½Åµµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à Á¦Á¶¾÷ü´Â ½ºÇÁ·¹ÀÌ, Å©¸², Á¤Á¦, ÁÖ»çÁ¦ µî È¿´ÉÀ» ³ôÀÎ ½Å±Ô Ä¡·á ¿¬±¸ °³¹ß(R&D)¿¡µµ Àû±Ø ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Á¦¾à ¾÷°èÀÇ ÇöÀúÇÑ ¼ºÀå, °øÁß º¸°ÇÀ» ÃËÁøÇÏ´Â Á¤ºÎÀÇ À¯¸®ÇÑ Á¤Ã¥ ÀÌÇà µî ±âŸ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ Ç×Áø±ÕÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : ¾àÁ¦ Ŭ·¡½ºº°

Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦9Àå SWOT ºÐ¼®

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå Porter's Five Forces ºÐ¼®

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global antifungal drugs market size reached US$ 15.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.

Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete's foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.

Antifungal Drugs Market Trends:

The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class and indication.

Breakup by Drug Class:

Azoles

Voriconazole (Vfend)

Posaconazole (Noxafil)

Clotrimazole (Canesten)

Isavuconazole (CRESEMBA)

Others

Echinocandins

Caspofungin (Cancidas)

Micafungin (Mycamine/ Funguard)

Others

Polyenes

Amphotericin (AmBisome)

Others

Allylamines

Terbinafine (Lamisil)

Others

Others

Breakup by Indication:

Dermatophytosis

Aspergillosis

Candidiasis

Invasive Candidiasis

Vulvovaginal Candidiasis (VVC)

Mouth/Throat/Esophageal Candidiasis

Others

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Antifungal Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Indication

8 Market Breakup by Region

9 SWOT Analysis

10 Value Chain Analysis

11 Porters Five Forces Analysis

12 Price Analysis

13 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â